Effect of triptolide on expression of receptor activator of nuclear factor-κB ligand in rat adjuvant induced arthritis

Abstract

The effect of triptolide (TP) on the expression of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) was explored in rat adjuvant induced arthritis (AA). AA was induced in Wistar rats. Arthritis rats were treated with TP and methotrexate (MTX) at the onset (day 9) of arthritis. On the peak of arthritis (day 24), the expression of RANKL and OPG protein in the joints and RANKL mRNA in peripheral blood mononuclear cells (PBMC) was detected. TNF-α and IL-1β levels in peripheral blood were determined. Bone erosion scores were also evaluated. The results showed that bone erosion scores in TP and MTX groups were lower than in AA group (P<0.01); The expression levels of RANKL in the synovium (P<0.01) and bone (P<0.05), and OPG level in synovium (P<0.05) were lower in TP group than in AA group (P<0.05). In TP group, the expression levels of RANKL mRNA and TNF-α, IL-1β in PBMC were lower than in AA group (allP<0.01). It was concluded that TP could inhibit rat adjuvant arthritis bone erosion by suppressing the expression of RANKL.

Keywords

arthritis, experimental / triptolide / methotrexate / receptor activator of nuclear factor-κB ligand / osteoprotegerin

References

[1] HuY H, WengG M, LuF E, et al.. Experimental investigation on triptolide induced apoptosis of synoviocytes in collagen induced arthritis rat. Chin J Rheumatology, 2004, 8: 131-134

[2] BolonB, CampagnuoloG, FeigeU. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci, 2002, 59: 1569-1576

[3] DaiS M, ShanZ Z, HanX H. Pathogenesis of bone erosion in rheumatoid arthritis. Chin J Rheumatology, 2002, 6: 201-203

[4] DequekerJ, MaenautK, VerwilghenJ, et al.. Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol, 1995, 13(Suppl. 12): S21-S26

[5] GoughA, SambrookP, DevlinJ, et al.. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol, 1998, 25: 1282-1289

[6] Saidenberg-KermanachN, Cohen-SolalM, BessisN, et al.. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine, 2004, 71: 9-13

[7] MiyashitaT, KawakamiA, NakashimaT, et al.. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol, 2004, 137: 430-436

[8] DaiS M, NishiokaK, YudohK. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumor necrosis factor alpha. Ann Rheum Dis, 2004, 63: 1379-1386